PTPN2 and neoplasm: reported a novel tumor immunotherapy strategy by targeting inhibition of the active sites of protein tyrosine phosphatases nonreceptor type 2 (PTPN2) and protein tyrosine phosphatases nonreceptor type 1 (PTPN1) by a small molecule inhibitor ABBV‐CLS‐484 (AC484), demonstrating strong potential for triggering powerful antitumor immunity.